Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy

@article{Kikushima2016ComparisonOI,
  title={Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy},
  author={Wataru Kikushima and Yoichi Sakurada and Atsushi Sugiyama and N. Tanabe and Atsuki Kume and H. Iijima},
  journal={Graefe's Archive for Clinical and Experimental Ophthalmology},
  year={2016},
  volume={255},
  pages={311-316}
}
PurposeTo compare the efficacy of two different initial treatment modalities on visual outcome, need for retreatment, and angiographic improvement during 12-month follow-up for polypoidal choroidal vasculopathy (PCV).MethodsA retrospective medical chart review was performed for 66 eyes from 66 patients with treatment-naïve PCV. Visual and angiographic improvements and the incidence of retreatment for recurrence or residual pathology were compared between two groups that underwent either… Expand
...
1
2
3
...

References

SHOWING 1-10 OF 20 REFERENCES
Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy
Two-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathy.
  • Yoichi Sakurada, H. Iijima
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2013
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
...
1
2
...